Abstract. Endocrine carcinomas (ECs) of the stomach reveal prominently aggressive behavior and have poor prognoses. Optimal treatments for gastric ECs have not been established because of the rarity of EC. In general, patients with gastric ECs die within a year of diagnosis in spite of surgical resections and subsequent chemotherapies. Liver metastases are the most common cause of death in gastric ECs, and their control is very important for improving the poor prognosis associated with the disease. In the present report, we describe a case in which a subject with stomach EC was diagnosed at an early stage. However, multiple liver metastases occurred soon after curative surgical resection and were treated via hepatic arterial infusion (HAI) with a combination of cisplatin and 5-fluorouracil. Consequently, the tumors almost completely disappeared. HAI therapy is a useful treatment for multiple metastatic liver tumors from gastric ECs devoid of metastases in other organs. Previously published therapies used to treat ECs of the stomach, including the ones used in the current case, are also discussed herein.
Introduction
Endocrine carcinomas (ECs) can arise in any gastrointestinal (GI) tract, however, their occurence is infrequent (1) . ECs of the stomach account for only 0.1 to 0.9% of all gastric carcinomas (2, 3) , and reveal prominently aggressive behavior, which differ from conventional gastric carcinomas (1, 4) . In general, EC patients have very poor prognoses in spite of surgical resections and subsequent chemotherapies, and die within a year of diagnosis (1, 4, 5) . However, with the occurrence of new anti-cancer agents and improvements in interventional treatments (6) , the number of long-term survivors with gastric ECs has increased. In the current study, we describe a case in which a subject with stomach EC, had multiple metastatic liver tumors which disappeared almost completely after hepatic arterial infusion (HAI) chemotherapy with the continuous administration of cisplatin (CDDP) and 5-fluorouracil (5-FU). In the 'Discussion', the previously reported treatments for ECs of the stomach are also reviewed.
Case report
Despite the lack of abdominal symptoms, a 76-year-old woman displayed a polypoid lesion on a screening barium meal study. A subsequent upper gastrointestinal endoscopy revealed an early-stage gastric carcinoma (a superficially spreading-type carcinoma with a protruding region) in the lesser curvature of the stomach body (Fig. 1) . A total gastrectomy with a regional lymph node (LN) dissection was performed, and postoperative pathological findings showed well-, and in some parts moderately-differentiated tubular adenocarcinomas with no LN metastases. According to the UICC TNM classification, the clinical stage was T1, N0, M0, and stage IA. Two months after the surgical resection, multiple liver tumors lacking swollen LNs were disclosed on an abdominal computed tomographic (CT) scan ( Fig. 2A) . No other tumors presented as primary foci in any other tissue except the liver. Biopsied specimens from the liver tumors revealed poorly differentiated carcinomas, which showed solid growth without glandular components. Additional histological examinations disclosed positive immunostaining for cytokeratin, the epithelial membrane antigen (EMA) and the neural cell adhesion molecule (NCAM) in the liver tumors, while an electron microscopic study showed multiple dense-cored granules in the cytoplasm of the poorly differentiated carcinoma cells (Fig. 3A) , suggesting that they were ECs. Re-examinations of the microscopic findings of the resected stomach defined poorly differentiated carcinomas, which revealed solid growth with gland-like structures, in a small area inside of extensively distributed tubular adenocarcinomas (Fig. 3B) . Histological examinations also revealed positive responses for cytokeratin, EMA, NCAM and small electron-dense granules in the poorly differentiated carcinoma cells of the stomach. Under the diagnosis that the multiple liver tumors were metastases from composite type gastric ECs, intensive chemotherapy using HAI (20 mg CDDP for 1 h and 250 mg 5-FU for 4 h, on days 1 to 5) via a subcutaneously implanted port, was performed for 3 continuous weeks, and ONCOLOGY REPORTS 17: 1077 -1081 , 2007 subsequently discontinued due to drug toxicity, nausea and vomiting. Even though the multiple liver tumors were growing to a large size before the start of chemotherapy (Fig. 2B) , these tumors disappeared almost completely 2 weeks after the end of the HAI therapy (Fig. 2C) . Soon, the patient was discharged and was followed-up in an outpatient clinic. She underwent HAI therapy with the administration of 20 mg CDDP and 250 mg 5-FU, once a week. However, 3 months following her hospital discharge, recurrences of liver tumors and new metastatic lesions, including those in the lung, pubic bone and para-aortic LNs, were disclosed on CT scans of the chest, abdomen and pelvis. A second round of chemotherapy using 80 mg S-1 on days 1 to 28, and the intravenous administration of 30 mg CDDP on days 7, 14, 21, and 28, was started immediately. Unfortunately, the diffuse liver tumor recurrences progressed, and the subject's condition worsened. She developed jaundice, and died of liver failure 10 months after surgery.
The patient had provided informed consent for liver biopsies, which were carried out to histologically type the tumors, in order to decide upon subsequent therapy.
Discussion
Bleak prognoses associated with stomach ECs are caused by prominent propensities for carcinomic metastases, which originate in the bottom of the gastric glands, spreading into the lymphatic and/or blood vessels even during the early stage of the disease (4,7). An optimal treatment for gastric ECs has not been established because of the rarity of the disease. However, in general, operable cases can undergo surgical resections of the invaded organs, followed by intensive chemotherapy. In cases with metastatic brain tumors, which are a common cause of death in gastric ECs, cranial radiation can be employed. The clinicopathological characteristics and the chemotherapeutic regimen for gastric ECs are summarized in Table I . Clinicopathological characteristics and chemotherapeutic regimen in 36 reported cases with gastric endocrine carcinoma. (3, 8, 9) . Since there are biological similarities between stomach ECs and small cell lung carcinomas (SCLCs), chemotherapeutic regimens for SCLCs have often been applied towards stomach ECs. A combination of CDDP and VP16, which is a standard regimen for extensive SCLCs (10), demonstrates a high response against gastric ECs. In contrast to SCLCs, ECs of the stomach are often accompanied by a non-small cell component, such as an adenocarcinoma or a squamous cell carcinoma (4, 5, 11) . Therefore, careful attention should be paid to the choice of anti-cancer agents for composite-type gastric ECs, as chemosensitivities vary for each carcinoma cell type. Moreover, the beneficial responses after chemotherapy are mostly short and transient, and may be followed by another chemotherapeutic regimen.
In the current case, as the first recurrence was limited to the liver and the recurrent hepatic tumors progressed very quickly, HAI therapy was chosen, which led to the almost complete disappearance of the massive tumors. While a few documented cases with liver metastases treated by HAI therapy using CDDP have resulted in favorable responses (9) , there are no reports showing almost complete responses after HAI therapy. In Japan, HAI chemotherapy with the continuous low-dose administration of CDDP and 5-FU (low-dose FP) (12) is frequently used to treat advanced, unresectable and multinodular forms of hepatocellular carcinoma (HCC). HAI with low-dose FP achieved more beneficial therapeutic results for these HCCs than transcatheter arterial chemoembolization (13, 14) . In addition to its own effect, CDDP amplifies the cell-killing effect of 5-FU, and the combination of CDDP and 5-FU, is widely used in chemotherapy for esophageal, colorectal and ovarian carcinomas. Unlike the intravenous high-dose administration of chemotherapeutic agents, HAI therapy through an implanted port can deliver anti-cancer agents in high concentrations directly to the liver, thereby decreasing the therapy's adverse effects. In contrast, a combined administration of 5-FU, epirubicin and mitomycin C (FEM) through HAI has been established for the treatment of liver metastases from gastric carcinomas (15) . FEM chemotherapy using HAI resulted in favorable responses against these metastatic liver tumors. Histologically, these stomach lesions are highly differentiated carcinomas, such as papillary, well-, and moderately-differentiated adenocarcinomas, in more than half of these cases. In contrast, advanced HCCs, which can be managed by HAI with low-dose FP, are composed of moderately to poorly differentiated carcinomas in most cases (16) . For the above-mentioned reasons, we selected HAI therapy with low-dose FP, which proved to be a useful option to regionally treat metastatic liver tumors from gastric ECs. Unfortunately, in the present case, soon after the almost complete disappearance of the multiple liver tumors, extended and aggressive recurrences occurred, followed by liver failure and subsequent death in spite of systemic Table I . Continued. 
ED, extensive disease (spread of disease beyond locoregional boundaries); LD, limited disease (limited in stomach including regional LN metastasis); ND, not described; CR, complete response; PR, partial response; NC, no change; PD, progressive disease; OS, overall survival; NED, no evidence of disease; AWD, alive with disease; DOD, died of disease; DOU, died of unknown cause; SG/TG/PG/DG, subtotal/total/partial/distal gastrectomy; RT; radiotherapy to brain; PBSCT, peripheral blood stem cell transplantation; hepatectomy; including lobectomy, segmentectomy and tumor resection; CDDP, cisplatin; 5-FU, 5-fluorouracil; CPA, cyclophosphamide; DXR, doxorubicin; EPI, epirubicin; MMC, mitomycin C; VCR, vincristine; PTX, paclitaxel.
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chemotherapy. Nevertheless, there is no doubt that the HAI therapy prolonged the patient's survival period.
In conclusion, we reported a case in which a subject with stomach EC, developed metastatic liver tumors, which were successfully treated by HAI therapy with low-dose FP. We reviewed previously published therapies for gastric ECs, and emphasized the importance of positive and intensive therapy even in cases of early-stage disease. Cumulative reports in the future are necessary to improve the bleak prognosis of gastric ECs.
